₹622.30
−1.55%NSE close, 16 Nov 2026
−21.11%
Supriya Lifescience is a small cap company in the Healthcare sector, listed on NSE under the symbol SUPRIYA. At ₹622.30 a share, the market values the whole company at ₹5,008 crore.
In FY26, it reported sales of ₹828 crore and a net profit of ₹209 crore, an operating margin of 35.5%. Over the last three years, sales grew 21.6% a year and net profit grew 32.5% a year.
The market values the company at 28.3 times its profit over the last twelve months and 4.03 times its book value; its return on equity is 14.3% and it has almost no borrowings.
Promoters hold 68.30% of the shares. Foreign institutions hold 6.44%, and domestic institutions, mutual funds among them, 5.47%.
Over the past year the share price has fallen 20.2%, and it is 42.7% below its 52-week high.
Companies of a similar size in the same sector include Aarti Pharmalabs, Healthcare Global Enterprises, Thyrocare Technologies and Suven Life Sciences.
₹ crore. Standalone figures: the company files no consolidated results.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Supriya Lifescience | ₹622.30 | ₹5,008 cr | 28.3 | 14.3% | +3.20% | −20.15% |
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 | 26.1% | +25.10% | +15.46% |
| Suven Life Sciences | ₹268.90 | ₹7,598 cr | n/a |
Transcript
Link of Recording
Appointment of Mr Mangesh Vaze as Chief Operating Officer, a Senior Management Personnel of the company w.e.f. November 06, 2026.
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 | 206 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 98.6 | 103 | 98.1 | 101 | 120 | 117 | 93.4 | 127 | 134 | 179 | 142 | 161 |
| Operating profit | 41.5 | 55.5 | 62.5 | 64.7 | 66.0 | 67.6 | 51.7 | 72.7 | 72.1 | 97.6 | 47.5 | 45.4 |
| Operating margin | 29.6% | 35.1% | 38.9% | 39.0% | 35.5% | 36.7% | 35.6% | 36.4% | 34.9% | 35.3% | 25.0% | 22.0% |
| Other income | 3.1 | 2.2 | 2.2 | 2.5 | 2.1 | 3.0 | 2.7 | 2.7 | 2.6 | 3.5 | 2.7 | 2.3 |
| Interest | 0.5 | 0.6 | 0.3 | 0.4 | 0.5 | 0.4 | 0.5 | 0.4 | 0.5 | 0.5 | 0.4 | 0.5 |
| Depreciation | 4.0 | 3.9 | 4.7 | 4.7 | 5.0 | 6.1 | 6.5 | 6.6 | 6.8 | 8.5 | 8.9 | 9.5 |
| Profit before tax | 40.1 | 53.2 | 59.8 | 62.1 | 62.6 | 64.1 | 47.4 | 68.3 | 66.9 | 92.1 | 40.8 | 37.8 |
| Tax | 10.3 | 16.2 | 15.1 | 15.9 | 15.8 | 13.7 | 12.6 | 17.9 | 17.3 | 17.9 | 16.8 | 8.5 |
| Net profit | 29.8 | 36.9 | 44.6 | 46.2 | 46.8 | 50.4 | 34.8 | 50.4 | 49.7 | 74.2 | 24.0 | 29.3 |
| EPS (₹) | 3.70 | 4.59 | 5.54 | 5.71 | 5.82 | 6.29 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 | 3.63 |
₹ crore, financial years to March.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales | 530 | 461 | 570 | 696 | 828 |
| Expenses | 316 | 332 | 397 | 436 | 534 |
| Operating profit | 214 | 129 | 173 | 261 | 294 |
| Operating margin | 40.4% | 28.0% | 30.4% | 37.4% | 35.5% |
| Other income | 7.6 | 9.5 | 10.7 | 9.8 | 11.5 |
| Interest | 4.2 | 3.1 | 2.4 | 1.7 | 1.9 |
| Depreciation | 10.1 | 11.8 | 15.8 | 20.4 | 28.4 |
| Profit before tax | 207 | 123 | 166 | 248 | 275 |
| Tax | 55.4 | 33.6 | 46.6 | 60.5 | 65.7 |
| Net profit | 152 | 89.9 | 119 | 188 | 209 |
| EPS (₹) | 18.86 | 11.17 | 14.80 | 23.35 | 25.98 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 48.8 | 165 | 186 | 60.9 |
| From investing | −59.8 | −152 | −176 | −38.8 |
| From financing | 150 | −8.2 | −9.9 | −8.5 |
| Spent on fixed assets | −59.9 | −162 | −152 | 0 |
| Free cash flow | −11.1 | 2.3 | 33.5 | 60.9 |
Margins, returns, debt, tax and cash.
| Line | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Net margin | 28.6% | 19.5% | 20.9% | 27.0% | 25.3% |
| Operating margin | 40.4% | 28.0% | 30.4% | 37.4% | 35.5% |
| Return on equity | – | 12.8% | 14.6% | 18.9% | 17.5% |
| Return on capital employed | – | 17.7% | 20.6% | 25.1% | 23.1% |
| Return on assets | – | 11.0% | 12.9% | 16.9% | 15.4% |
| Debt to equity | – | 0.02 | 0.00 | 0.00 | 0.00 |
| Interest coverage | 50.30 | 41.10 | 70.90 | 148.00 | 146.40 |
| Debt to assets | – | 0.02 | 0.00 | 0.00 | 0.00 |
| Current ratio | – | 4.85 | 5.17 | 5.32 | 4.40 |
| Quick ratio | – | 3.65 | 4.06 | 3.88 | 3.08 |
| Cash ratio | – | 0.89 | 0.89 | 0.93 | 0.31 |
| Asset turnover | – | 0.56 | 0.62 | 0.63 | 0.61 |
| Fixed asset turnover | – | 1.81 | 1.88 | 1.54 | 1.21 |
| Inventory turnover | – | – | 2.60 | 1.80 | 1.60 |
| Receivables turnover | – | 5.40 | 5.10 | 5.20 | 3.80 |
| Gross margin | – | – | 61.1% | 69.7% | 69.3% |
| Cash from operations to profit | 32.0% | – | – | 88.0% | 89.0% |
| Effective tax rate | 26.8% | 27.2% | 28.1% | 24.4% | 23.9% |
| -84.2% |
| +30.40% |
| +39.45% |
| Nephrocare Health Services | ₹642.00 | ₹6,456 cr | 50.4 | 10.8% | n/a | n/a |
|---|
| Sun Pharma Advanced Research Company | ₹195.84 | ₹6,355 cr | 3.9 | 113.4% | +282.10% | +45.52% |
|---|
| Senores Pharmaceuticals | ₹1,147.80 | ₹5,286 cr | 38.2 | 13.8% | +18.90% | +42.61% |
|---|
| Advanced Enzyme Technologies | ₹280.85 | ₹3,122 cr | 18.3 | 10.3% | +16.20% | −9.69% |
|---|
Financial Results for the quarter and half year ended September 30, 2026.
The financial results for the period ended September 30, 2026.
General Updates under Regulation 30 of SEBI (LODR) Regulations, 2015.
Schedule of meet
General Updates on ESG Ratings by CRISIL
Proceedings of Annual General Meeting held on September 24, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the…